Cap for an inhalation device
Latest Glaxo Group Limited Patents:
- Method of producing a recombinant protein
- Antigen binding proteins
- Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
- Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
- Compounds
Description
FIG. 1 is a bottom, right perspective view of a cap for an inhalation device showing my new design;
FIG. 2 is a bottom plan view thereof;
FIG. 3 is a top plan view thereof;
FIG. 4 is a left elevational view thereof;
FIG. 5 is a front elevational view thereof; and,
FIG. 6 is a rear elevational view thereof.
The broken line showing of environment in all views is for illustrative purposes only and forms no part of the claimed design.
Referenced Cited
Patent History
Patent number: D370726
Type: Grant
Filed: Nov 22, 1994
Date of Patent: Jun 11, 1996
Assignee: Glaxo Group Limited (London)
Inventor: John M. Padfield (Cambridge)
Primary Examiner: Louis S. Zarfas
Assistant Examiner: Frank Martinez
Law Firm: Bacon & Thomas
Application Number: 0/31,259
Type: Grant
Filed: Nov 22, 1994
Date of Patent: Jun 11, 1996
Assignee: Glaxo Group Limited (London)
Inventor: John M. Padfield (Cambridge)
Primary Examiner: Louis S. Zarfas
Assistant Examiner: Frank Martinez
Law Firm: Bacon & Thomas
Application Number: 0/31,259
Classifications
Current U.S. Class:
Respirator, Vaporizer, Or Inhalation Tube (4) (D24/110);
128/20021